Advertisement

Topics

After Axovant shock, Roivant pens diabetes deal with Poxel

06:09 EST 13 Feb 2018 | PMLIVE

Acquires Merck Serono’s diabetes candidate imeglimin as part of the deal

Original Article: After Axovant shock, Roivant pens diabetes deal with Poxel

NEXT ARTICLE

More From BioPortfolio on "After Axovant shock, Roivant pens diabetes deal with Poxel"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...